Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML)

NCT00273884 is registered in ClinicalTrials.gov with Xanthus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00273884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00273884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Open-Label Study of Amonafide L-Malate in Combination With Cytarabine in Subjects With Secondary Acute Myeloid Leukemia (AML)
Lead sponsor
Xanthus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
April 30, 2009
Enrollment
80
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia